Skip to main content

Professor Mark Boyd

Mark Boyd
Chailr of Medicine
Adelaide Medical School
Faculty of Health and Medical Sciences

Professor Boyd is an internationally recognised infectious disease expert. He has led project teams in HIV research in Thailand, as well as at the Kirby Institute for infection and immunity at the University of New South Wales. He has had a key role in two major, multicentre, international randomised clinical trials (‘SECOND-LINE’ and ‘Encore1’) sponsored by the Kirby Institute, which have brought changes to the WHO guidelines on the antiretroviral management of HIV infection in adults and adolescents.

Until recently Professor Boyd was an Associate Professor at the Kirby Institute, a consultant physician in HIV Medicine and Infectious Diseases and a Visiting Medical Officer in inner Sydney as well as regional NSW.

Connect With Me

External Profiles

Professor Mark Boyd

Professor Boyd is an internationally recognised infectious disease expert. He has led project teams in HIV research in Thailand, as well as at the Kirby Institute for infection and immunity at the University of New South Wales. He has had a key role in two major, multicentre, international randomised clinical trials (‘SECOND-LINE’ and ‘Encore1’) sponsored by the Kirby Institute, which have brought changes to the WHO guidelines on the antiretroviral management of HIV infection in adults and adolescents.

Until recently Professor Boyd was an Associate Professor at the Kirby Institute, a consultant physician in HIV Medicine and Infectious Diseases and a Visiting Medical Officer in inner Sydney as well as regional NSW.

Research

In 2014 he was awarded the Frank Fenner Award for Advanced Research in Infectious Diseases by the Australasian Society for Infectious Diseases. He has published more than 100 papers, book chapters, reviews and commentaries and been an investigator on grants worth in excess of $17 million.

“I am a great believer in the conduct of research that aims to make a clear and positive difference in peoples’ lives,” Professor Boyd says. “High quality clinical research and the rapid translation of robust research findings into clinical practice is key to driving improvements in patient outcomes and public health. I am delighted to have been offered this unique position at the Lyell McEwin, where I aim to combine academic rigour with a commitment to the highest quality service delivery to the population of the NAHLN.”

Appointments

Date Position Institution name
2015 - 2016 Visiting Medical Officer Murrumbidgee Health District
2015 - 2016 Visiting Medical Officer Albury Wodonga Health District
2013 - 2016 Associate Professor University of New South Wales
2007 - 2012 Clinical Project Leader St Vincent's Hospital
2004 - 2007 Senior Consultant in Infectious Diseases and Microbiology Flinders Medical Centre
2000 - 2004 Clinical Project Leader HIV Netherlands Australia Thailand Research Collaboration

Awards and Achievements

Date Type Title Institution Name Country Amount
2014 Award The Frank Fenner Award for Advanced Research in Infectious Diseases Australasian Society for Infectious Diseases (ASID) Inc.
2014 Award Outstanding Reviewer for 2013
1986 Award The Alfred Houston Senior Prize in Philosophy University of Tasmania

Education

Date Institution name Country Title
2006 Flinders University Australia (MHID) - Master of Health and International Development
2001 - 2006 University of New South Wales Australia MD - Doctor of Medicine
1997 University of Alabama (USA) and Universidad Peruana Cayetano-Heredia (Perú) Peru and United States DCTM&H - Dip. In Clinical. Trop. Med. and Hygiene
1987 - 1992 Flinders University Australia BM, BS Medicine, Surgery
1983 - 1986 University of Tasmania Australia BA Philosophy - English Literature

Certifications

Date Title Institution name Country
2013 Graduate Certificate in University Learning and Te University of New South Wales Australia
2011 Certificate for Ethics Training for Human Research Monash University Australia
1995 Fellowship Royal Australasian College of Physicians Australia

Research Interests

Journals

Year Citation
2018 Yao, A., Moore, C., Lim, P., Molina, J. -M., Madero, J., Kerr, S., . . . Boyd, M. (2018). Metabolic profiles of individuals switched to second-line antiretroviral therapy after failing standard first-line therapy for treatment of HIV-1 infection in a randomized, controlled trial.. Antiviral therapy, 23(1), 21-32.
DOI
2018 Boyd, M., Cooper, D., & Gilks, C. (2018). Towards a universal second-line fixed-dose combination ART. The Lancet HIV, 5(1), e3-e5.
DOI Scopus2 Europe PMC2
2018 Stockdale, A., Saunders, M., Boyd, M., Bonnett, L., Johnston, V., Wandeler, G., . . . Geretti, A. (2018). Effectiveness of protease inhibitor/nucleos(t)ide reverse transcriptase inhibitor-based second-line antiretroviral therapy for the treatment of HIV-1 infection in sub-Saharan Africa: systematic review and meta-analysis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 66(12), 1846-1857.
DOI
2018 Boyd, M., & Cooper, D. (2018). Combination ART: are two drugs as good as three?. The Lancet, 391(10123), 817-819.
DOI
2018 Mwasakifwa, G., Moore, C., Carey, D., Amin, J., Penteado, P., Losso, M., . . . Boyd, M. (2018). Relationship between untimed plasma lopinavir concentrations and virological outcome on second-line antiretroviral therapy. AIDS, 32(3), 357-361.
DOI
2017 Petoumenos, K., Choi, J., Hoy, J., Kiertiburanakul, S., Ng, O., Boyd, M., . . . Law, M. (2017). CD4:CD8 ratio comparison between cohorts of HIV-positive Asians and Caucasians upon commencement of antiretroviral therapy. Antiviral Therapy, 22(8), 659-668.
DOI
2017 Boyd, M., Mocroft, A., Ryom, L., d'Arminio Monforte, A., Sabin, C., El-Sadr, W., . . . Law, M. (2017). Cardiovascular disease (CVD) and chronic kidney disease (CKD) event rates in HIV-positive persons at high predicted CVD and CKD risk: a prospective analysis of the D:A:D observational study. PLoS Medicine, 14(11), e1002424-1-e1002424-14.
DOI Scopus1 Europe PMC1
2017 Bell, S., Mena, G., Dean, J., Boyd, M., Gilks, C., & Gartner, C. (2017). Vaporised nicotine and tobacco harm reduction for addressing smoking among people living with HIV: A cross-sectional survey of Australian HIV health practitioners’ attitudes. Drug and Alcohol Dependence, 177, 67-70.
DOI
2017 Lau, A., Kong, F., Fairley, C., Donovan, B., Chen, M., Bradshaw, C., . . . Hocking, J. (2017). Treatment efficacy of azithromycin 1 g single dose versus doxycycline 100 mg twice daily for 7 days for the treatment of rectal chlamydia among men who have sex with men - a double-blind randomised controlled trial protocol. BMC Infectious Diseases, 17(1), 35-1-35-9.
DOI Scopus2 WoS3 Europe PMC3
2017 Aung, N., Hanson, J., Kyi, T., Htet, Z., Cooper, D., Boyd, M., . . . Saw, H. (2017). HIV care in Yangon, Myanmar; successes, challenges and implications for policy. AIDS Research and Therapy, 14(1), 1-7.
DOI Scopus1 Europe PMC1
2017 Rhee, S., Varghese, V., Holmes, S., Van Zyl, G., Steegen, K., Boyd, M., . . . Shafer, R. (2017). Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration. EBioMedicine, 18, 225-235.
DOI Scopus6 Europe PMC5
2017 Boyd, M. (2017). Body composition substudy of the SECOND-LINE study – Author's reply. The Lancet HIV, 4(6), e240.
DOI
2017 Bell, S., Dean, J., Gilks, C., Boyd, M., Fitzgerald, L., Mutch, A., . . . Gartner, C. (2017). Tobacco harm reduction with vaporised nicotine (THRiVe): The study protocol of an uncontrolled feasibility study of novel nicotine replacement products among people living with HIV who smoke. International Journal of Environmental Research and Public Health, 14(7), 799.
DOI Scopus1 Europe PMC1
2017 Boyd, M., & Cooper, D. (2017). Long-acting injectable ART: next revolution in HIV?. The Lancet, 390(10101), 1468-1470.
DOI Scopus2 Europe PMC2
2017 Thit, S., Aung, N., Htet, Z., Boyd, M., Saw, H., Anstey, N., . . . Hanson, J. (2017). The clinical utility of the urine-based lateral flow lipoarabinomannan assay in HIV-infected adults in Myanmar: an observational study. BMC Medicine, 15(1), 145-1-145-11.
DOI Scopus1 Europe PMC1
2017 Puhr, R., Petoumenos, K., Youds, D., Law, M., Templeton, D., Ellis, D., . . . Bargh, K. (2017). The impact of changes in HIV management guidelines on time to treatment initiation in Australia. HIV Medicine, 18(9), 701-703.
DOI Scopus1
2017 Boyd, M., Amin, J., Mallon, P., Kumarasamy, N., Lombaard, J., Wood, R., . . . Cooper, D. (2017). Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study. The Lancet HIV, 4(1), e13-e20.
DOI Scopus4 WoS3 Europe PMC3
2016 Zaunders, J., Danta, M., Bailey, M., Mak, G., Marks, K., Seddiki, N., . . . Koelsch, K. (2016). CD4⁺ T follicular helper and IgA⁺ B cell numbers in gut biopsies from HIV-infected subjects on antiretroviral therapy are similar to HIV-uninfected individuals. Frontiers in Immunology, 7(OCT), 438.
DOI Scopus5 Europe PMC2
2016 Boyd, M., Cooper, D., Crock, E., Crooks, L., Giles, M., Grulich, A., . . . Yarwood, T. (2016). Sexual transmission of HIV and the law: An Australian medical consensus statement. Medical Journal of Australia, 205(9), 409-412.
DOI
2016 Winston, A., Stöhr, W., Antinori, A., Arenas-Pinto, A., Llibre, J., Amieva, H., . . . Palmisiano, L. (2016). Host and disease factors are associated with cognitive function in European HIV-infected adults prior to initiation of antiretroviral therapy. HIV Medicine, 17(6), 471-478.
DOI Scopus3 Europe PMC4
2016 Lambert-Niclot, S., George, E., Pozniak, A., White, E., Schwimmer, C., Jessen, H., . . . Aagaard, B. (2016). Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: Raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART. Journal of Antimicrobial Chemotherapy, 71(4), 1056-1062.
DOI Scopus7 Europe PMC7
2016 Boyd, M., & Cooper, D. (2016). Tenofovir alafenamide: safer, but questions remain. The Lancet HIV, 3(4), e148-e149.
DOI Scopus1
2016 Lam, E., Moore, C., Gotuzzo, E., Nwizu, C., Kamarulzaman, A., Chetchotisakd, P., . . . Boyd, M. (2016). Antiretroviral resistance after first-line antiretroviral therapy failure in diverse HIV-1 subtypes in the SECOND-LINE study. AIDS Research and Human Retroviruses, 32(9), 841-850.
DOI Scopus3 Europe PMC3
2016 Achhra, A., Mwasakifwa, G., Amin, J., & Boyd, M. (2016). Efficacy and safety of contemporary dual-drug antiretroviral regimens as first-line treatment or as a simplification strategy: a systematic review and meta-analysis. The Lancet HIV, 3(8), e351-e360.
DOI Scopus22 Europe PMC14
2016 Alvarez, E., Belloso, W., Boyd, M., Inkaya, A., Hsieh, E., Kambugu, A., . . . Mallon, P. (2016). Which HIV patients should be screened for osteoporosis: An international perspective. Current Opinion in HIV and AIDS, 11(3), 268-276.
DOI Scopus4 Europe PMC3
2016 Boyd, M., & Cooper, D. (2016). Novel antiretroviral agents and universal access to HIV care. The Lancet HIV, 3(1), e2-e3.
DOI
2015 Boyd, M., Moore, C., Molina, J., Wood, R., Madero, J., Wolff, M., . . . Cooper, D. (2015). Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: An exploratory analysis. The Lancet HIV, 2(2), 42-51.
DOI Scopus26 Europe PMC20
2015 Cummins, N., Neuhaus, J., Chu, H., Neaton, J., Wyen, C., Rockstroh, J., . . . Badley, A. (2015). Investigation of Efavirenz Discontinuation in Multi-ethnic Populations of HIV-positive Individuals by Genetic Analysis. EBioMedicine, 2(7), 706-712.
DOI Scopus9 Europe PMC6
2015 Boyd, M., Donovan, B., Prestage, G., Chen, M., Petoumenos, K., Gray, R., . . . Klausner, J. (2015). Is it time to rethink syphilis control?. Clinical Infectious Diseases, 60(2), 325-326.
DOI Scopus4 Europe PMC3
2015 Templeton, D., Wright, S., McManus, H., Lawrence, C., Russell, D., Law, M., . . . Guelfi, G. (2015). Antiretroviral treatment use, co-morbidities and clinical outcomes among Aboriginal participants in the Australian HIV Observational Database (AHOD). BMC Infectious Diseases, 15(1), 326.
DOI Scopus2 Europe PMC2
2015 McManus, H., Hoy, J., Woolley, I., Boyd, M., Kelly, M., Mulhall, B., . . . Law, M. (2015). Erratum: Recent trends in early stage response to combination antiretroviral therapy in Australia. Antiviral Therapy, 20(2), 255.
DOI
2015 Wright, S., Law, M., Cooper, D., Keen, P., McDonald, A., Middleton, M., . . . Roth, N. (2015). Temporal trends of time to antiretroviral treatment initiation, interruption and modification: Examination of patients diagnosed with advanced HIV in Australia. Journal of the International AIDS Society, 18(1), 19463.
DOI Scopus4 Europe PMC2
2015 McManus, H., Hoy, J., Woolley, I., Boyd, M., Kelly, M., Mulhall, B., . . . Law, M. (2015). Recent trends in early stage response to combination antiretroviral therapy in Australia. Antiviral Therapy, 20(2), 131-139.
DOI Scopus3 WoS2
2015 Amin, J., Boyd, M., Kumarasamy, N., Moore, C., Losso, M., Nwizu, C., . . . Cooper, D. (2015). Erratum: Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection (PLoS ONE (2015)10:2 (e0118228) Doi: 10.1371/journal.pone.0118228 )). PLoS ONE, 10(10), e0140623.
DOI Scopus3
2015 Boyd, M., & Cooper, D. (2015). The LATTE study: A provocative brew. The Lancet Infectious Diseases, 15(10), 1116-1117.
DOI
2015 Amin, J., Becker, S., Belloso, W., Boffito, M., Cooper, D., Crabtree-Ramirez, B., . . . Dolan, M. (2015). Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study. The Lancet Infectious Diseases, 15(7), 793-802.
DOI Scopus37 Europe PMC22
2015 Amin, J., Boyd, M., Kumarasamy, N., Moore, C., Losso, M., Nwizu, C., . . . Cooper, D. (2015). Raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: A randomised open label study for the treatment of HIV-1 infection. PLoS ONE, 10(2), e0118228.
DOI Scopus14 Europe PMC11
2015 Han, N., Wright, S., O'Connor, C., Hoy, J., Ponnampalavanar, S., Grotowski, M., . . . Zhang, F. (2015). HIV and aging: Insights from the Asia Pacific HIV Observational Database (APHOD). HIV Medicine, 16(3), 152-160.
DOI Scopus5 Europe PMC3
2015 Bernardino, J. I., Mocroft, A., Mallon, P. W., Wallet, C., Gerstoft, J., Russell, C., . . . Arribas, J. R. (2015). Bone mineral density and inflammatory and bone biomarkers after darunavir–ritonavir combined with either raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial. The Lancet HIV, 2(11), e464-e473.
DOI
2015 Beyrer, C., Birx, D. L., Bekker, L. -G., Barré-Sinoussi, F., Cahn, P., Dybul, M. R., . . . Montaner, J. S. (2015). The Vancouver Consensus: antiretroviral medicines, medical evidence, and political will. The Lancet, 386(9993), 505-507.
DOI
2014 Raffi, F., Babiker, A. G., Richert, L., Molina, J. -M., George, E. C., Antinori, A., . . . Pozniak, A. (2014). Ritonavir-boosted darunavir combined with raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial. The Lancet, 384(9958), 1942-1951.
DOI
2014 Haskelberg, H., Pocock, N., Amin, J., Ebeling, P., Emery, S., & Carr, A. (2014). Hip structural parameters over 96 weeks in HIV-infected adults switching treatment to Tenofovir-Emtricitabine or Abacavir-Lamivudine. PLoS ONE, 9(4), e94858-1-e94858-8.
DOI
2014 Haskelberg, H., Cordery, D., Amin, J., Kelleher, A., Cooper, D., & Emery, S. (2014). HLA alleles association with changes in bone mineral density in HIV-1-infected adults changing treatment to Tenofovir-Emtricitabine or Abacavir-Lamivudine. PLoS ONE, 9(3), e93333-1-e93333-7.
DOI
2014 McManus, H., Petoumenos, K., Franic, T., Kelly, M., Watson, J., O’Connor, C., . . . Law, M. (2014). Determinants of Suicide and Accidental or Violent Death in the Australian HIV Observational Database. PLoS ONE, 9(2), e89089.
DOI
2014 McManus, H., Petoumenos, K., Brown, K., Baker, D., Russell, D., Read, T., . . . Law, M. (2014). Loss to follow-up in the Australian HIV Observational Database. Antiviral Therapy, 20(7), 731-741.
DOI
2014 Achhra, A., Boyd, M., Law, M., Matthews, G., Kelleher, A., & Cooper, D. (2014). Moving away from ritonavir, abacavir, tenofovir, and efavirenz (RATE) - Agents that concern prescribers and patients: A feasibility study and call for a trial. PLoS ONE, 9(6), e99530.
DOI Scopus3 Europe PMC2
2014 Amin, J., Becker, S., Belloso, W., Boffito, M., Cooper, D., Crabtree-Ramirez, B., . . . Dolan, M. (2014). Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): A randomised, double-blind, placebo-controlled, non-inferiority trial. The Lancet, 383(9927), 1474-1482.
DOI Scopus75 Europe PMC59
2014 Wright, S., Hoy, J., Mulhall, B., O'connor, C., Petoumenos, K., Read, T., . . . Boyd, M. (2014). Determinants of viremia copy-years in people with HIV/AIDS after initiation of antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes, 66(1), 55-64.
DOI Scopus10 WoS7 Europe PMC8
2014 Holt, S., Gracey, D., Levy, M., Mudge, D., Irish, A., Walker, R., . . . Boyd, M. (2014). A consensus statement on the renal monitoring of Australian patients receiving tenofovir based antiviral therapy for HIV/HBV infection. AIDS Research and Therapy, 11(1), 35-1-35-10.
DOI Scopus4 WoS4 Europe PMC3
2014 Revell, A., Boyd, M., Wang, D., Emery, S., Gazzard, B., Reiss, P., . . . Larder, B. (2014). A comparison of computational models with and without genotyping for prediction of response to second-line HIV therapy. HIV Medicine, 15(7), 442-448.
DOI Scopus2
2014 Haskelberg, H., Mallon, P., Hoy, J., Amin, J., Moore, C., Phanuphak, P., . . . Emery, S. (2014). Bone mineral density over 96 weeks in adults failing first-line therapy randomised to raltegravir/lopinavir/ritonavir compared to standard second-line therapy. Journal of Acquired Immune Deficiency Syndromes, 67(2), 161-168.
DOI Scopus12 Europe PMC11
2013 Wright, S., Boyd, M., Yunihastuti, E., Law, M., Sirisanthana, T., Hoy, J., . . . Petoumenos, K. (2013). Rates and factors associated with major modifications to first-line combination antiretroviral therapy: results from the Asia-Pacific region. PLoS ONE, 8(6), e64902-1-e64902-12.
DOI Scopus12 WoS8 Europe PMC11
2013 Achhra, A., & Boyd, M. (2013). Antiretroviral regimens sparing agents from the nucleoside(tide) reverse transcriptase inhibitor class: A review of the recent literature. AIDS Research and Therapy, 10(1), 33.
DOI Scopus20 Europe PMC14
2013 Martin, A., Moore, C., Mallon, P., Hoy, J., Emery, S., Belloso, W., . . . Second-line study team. (2013). HIV lipodystrophy in participants randomised to lopinavir/ritonavir (LPV/r) +2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI) or LPV/r + raltegravir as second-line antiretroviral therapy. PLoS One, 8(10), e77138-1-e77138-9.
DOI Scopus11 WoS9 Europe PMC8
2013 Boyd, M., & Cooper, D. (2013). SPRING-2 the future of antiretroviral therapy. The Lancet Infectious Diseases, 13(11), 908-909.
DOI Scopus4 Europe PMC3
2013 Martin, A., Moore, C., Mallon, P., Hoy, J., Emery, S., Belloso, W., . . . Boyd, M. (2013). Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapy. AIDS, 27(15), 2403-2411.
DOI Scopus24 WoS27 Europe PMC20
2013 Boyd, M., & Donovan, B. (2013). Antiretroviral therapy: Dolutegravir sets SAIL(ING). The Lancet, 382(9893), 664-666.
DOI Scopus2
2013 Schneider, K., Nwizu, C., Kaplan, R., Anderson, J., Wilson, D., Emery, S., . . . Boyd, M. (2013). The Potential Cost and Benefits of Raltegravir in Simplified Second-Line Therapy among HIV Infected Patients in Nigeria and South Africa. PLoS ONE, 8(2), e54435.
DOI Scopus1 Europe PMC1
2013 Byakwaga, H., Petoumenos, K., Ananworanich, J., Zhang, F., Boyd, M., Sirisanthana, T., . . . Emery, S. (2013). Predictors of clinical progression in HIV-1-infected adults initiating combination antiretroviral therapy with advanced disease in the Asia-Pacific region: Results from the TREAT Asia HIV Observational Database. Journal of the International Association of Providers of AIDS Care, 12(4), 270-277.
DOI Scopus3 Europe PMC2
2013 Jansson, J., Wilson, D., Carr, A., Petoumenos, K., & Boyd, M. (2013). Currently available medications in resource-rich settings may not be sufficient for lifelong treatment of HIV. AIDS, 27(8), 1245-1251.
DOI Scopus10 Europe PMC8
2013 Boyd, M. (2013). Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): A randomised, open-label, non-inferiority study. The Lancet, 381(9883), 2091-2099.
DOI Scopus96 Europe PMC66
2013 Wright, S., Petoumenos, K., Boyd, M., Carr, A., Downing, S., O'Connor, C., . . . Law, M. (2013). Ageing and long-term CD4 cell count trends in HIV-positive patients with 5 years or more combination antiretroviral therapy experience. HIV Medicine, 14(4), 208-216.
DOI Scopus12 Europe PMC9
2013 Petoumenos, K., van Leuwen, M., Vajdic, C., Woolley, I., Chuah, J., Templeton, D., . . . Law, M. (2013). Cancer, immunodeficiency and antiretroviral treatment: results from the Australian HIV Observational Database (AHOD). HIV Medicine, 14(2), 77-84.
DOI
2012 McManus, H., O'Connor, C., Boyd, M., Broom, J., Russell, D., Watson, K., . . . Law, M. (2012). Long-Term Survival in HIV Positive Patients with up to 15 Years of Antiretroviral Therapy. PLoS ONE, 7(11), e48839.
DOI Scopus35 Europe PMC30
2012 Avihingsanon, A., Van Der Lugt, J., Singphore, U., Gorowara, M., Boyd, M., Ananworanich, J., . . . Ruxrungtham, K. (2012). Pharmacokinetics and 48 week efficacy of adjusted dose indinavir/ritonavir in rifampicin-treated HIV/tuberculosis-coinfected patients: A pilot study. AIDS Research and Human Retroviruses, 28(10), 1170-1176.
DOI Scopus1
2012 Boyd, M., & Mohapi, L. (2012). Stretching delivery of HIV health services. The Lancet, 380(9845), 865-867.
DOI
2012 Haskelberg, H., Hoy, J., Amin, J., Ebeling, P., Emery, S., Carr, A., . . . Woolley, I. (2012). Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudine. PLoS ONE, 7(6), 1-9.
DOI Scopus53 Europe PMC44
2012 Boyd, M. (2012). Dolutegravir-a promising antiretroviral in development. The Lancet Infectious Diseases, 12(2), 90-91.
DOI Scopus7 Europe PMC4
2012 Boyd, M., & Cooper, D. (2012). Optimisation of HIV care and service delivery: Doing more with less. The Lancet, 380(9856), 1860-1866.
DOI Scopus11 Europe PMC8
2012 Carey, D., Pett, S., Bloch, M., Wand, H., MacRae, K., Beileiter, K., . . . Cooper, D. (2012). A randomized study of pharmacokinetics, efficacy, and safety of 2 raltegravir plus atazanavir strategies in ART-treated adults. Journal of Acquired Immune Deficiency Syndromes, 60(2), 143-149.
DOI Scopus16 Europe PMC10
2011 Byakwaga, H., Kelly, M., Purcell, D., French, M., Amin, J., Lewin, S., . . . Emery, S. (2011). Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4<sup>+</sup>T-cell response: A randomized controlled trial. Journal of Infectious Diseases, 204(10), 1532-1540.
DOI Scopus44 WoS41 Europe PMC34
2011 Revell, A., Wang, D., Boyd, M., Emery, S., Pozniak, A., De Wolf, F., . . . Larder, B. (2011). The development of an expert system to predict virological response to HIV therapy as part of an online treatment support tool. AIDS, 25(15), 1855-1863.
DOI Scopus18 Europe PMC12
2011 Martin, A., Amin, J., Emery, S., Baker, D., Carr, A., Cooper, D., & Bloch, M. (2011). Predictors of Limb Fat Gain in HIV Positive Patients Following a Change to Tenofovir-Emtricitabine or Abacavir-Lamivudine. PLoS ONE, 6(10), e26885.
DOI
2011 Kowalska, J. D., Friis-Møller, N., Kirk, O., Bannister, W., Mocroft, A., Sabin, C., . . . Lundgren, J. D. (2011). The Coding Causes of Death in HIV (CoDe) Project. Epidemiology, 22(4), 516-523.
DOI
2011 Law, M., Woolley, I., Templeton, D., Roth, N., Chuah, J., Mulhall, B., . . . Australian HIV Observational Database (AHOD).. (2011). Trends in detectable viral load by calendar year in the Australian HIV observational database. Journal of the International AIDS Society, 14(1), 10-1-10-7.
DOI
2011 Wright, S. T., Carr, A., Woolley, I., Giles, M., Hoy, J., Cooper, D. A., & Law, M. G. (2011). CD4 Cell Responses to Combination Antiretroviral Therapy in Patients Starting Therapy at High CD4 Cell Counts. JAIDS Journal of Acquired Immune Deficiency Syndromes, 58(1), 72-79.
DOI
2011 Wilson, D., Grulich, A., & Boyd, M. (2011). Overly optimistic forecasts for the impact of treatment of hiv prevention for men who have sex with men. Clinical Infectious Diseases, 53(6), 611-612.
DOI Scopus2 Europe PMC1
2010 Martin, A., Amin, J., Cooper, D. A., Carr, A., Kelleher, A. D., Bloch, M., . . . Emery, S. (2010). Abacavir does not affect circulating levels of inflammatory or coagulopathic biomarkers in suppressed HIV: a randomized clinical trial. AIDS, 24(17), 2657-2663.
DOI
2010 Zhou, J., Li, P., Kumarasamy, N., Boyd, M., Chen, Y., Sirisanthana, T., . . . Pujari, S. (2010). Deferred modification of antiretroviral regimen following documented treatment failure in Asia: Results from the TREAT Asia HIV Observational Database (TAHOD). HIV Medicine, 11(1), 31-39.
DOI Scopus19 Europe PMC11
2010 Carey, D., Amin, J., Boyd, M., Petoumenos, K., & Emery, S. (2010). Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir: Systematic review and meta-analysis of randomized controlled trials. Journal of Antimicrobial Chemotherapy, 65(9), 1878-1888.
DOI Scopus30 Europe PMC19
2010 Boyd, M., & Nwizu, C. (2010). Operational research in HIV priority areas: the African way. The Lancet, 376(9734), 4-6.
DOI Scopus1 Europe PMC2
2010 Boyd, M., & Hill, A. (2010). Clinical management of treatment-experienced, HIV/AIDS patients in the combination antiretroviral therapy era. PharmacoEconomics, 28(SUPPL. 1), 17-34.
DOI Scopus12 Europe PMC2
2010 Boyd, M. (2010). Current and future management of treatment failure in low- and middle-income countries. Current Opinion in HIV and AIDS, 5(1), 83-89.
DOI Scopus14 Europe PMC9
2009 Boyd, M. (2009). Improvements in antiretroviral therapy outcomes over calendar time. Current Opinion in HIV and AIDS, 4(3), 194-199.
DOI Scopus34 Europe PMC30
2009 Byakwaga, H., Murray, J., Petoumenos, K., Kelleher, A., Law, M., Boyd, M., . . . Cooper, D. (2009). Evolution of CD4<sup>+</sup> T cell count in HIV-1-infected adults receiving antiretroviral therapy with sustained long-term virological suppression. AIDS Research and Human Retroviruses, 25(6), 569-576.
DOI Scopus4 Europe PMC6
2009 Byakwaga, H., Zhou, J., Petoumenos, K., Law, M., Boyd, M., Emery, S., . . . Mallon, P. (2009). Effect of nucleoside reverse transcriptase inhibitors on CD4 T-cell recovery in HIV-1-infected individuals receiving long-term fully suppressive combination antiretroviral therapy. HIV Medicine, 10(3), 143-151.
DOI Scopus3 Europe PMC2
2009 Boyd, M., Emery, S., & Cooper, D. (2009). Antiretroviral roll-out: the problem of second-line therapy. The Lancet, 374(9685), 185-186.
DOI Scopus16 Europe PMC13
2008 Boyd, M., Truman, M., Hales, G., Anderson, J., Dwyer, D., & Carr, A. (2008). A randomized study to evaluate injection site reactions using three different enfuvirtide delivery mechanisms (the OPTIONS study). Antiviral Therapy, 13(3), 449-453.
Scopus8 Europe PMC5
2008 Colebunders, R., French, M., Oelrichs, R., & Boyd, M. (2008). Editorial introductions. Current Opinion in HIV and AIDS, 3(4), vii-viii.
DOI
2008 Boyd, M., & Pett, S. (2008). HIV fusion inhibitors: A review. Australian Prescriber, 31(3), 66-69.
Scopus1
2008 Boyd, M., & Byakwaga, H. (2008). Considering the benefits of disease-specific interventions on overall public health. The Lancet Infectious Diseases, 8(5), 278.
DOI Scopus1 Europe PMC1
2008 Oelrichs, R., & Boyd, M. (2008). Evidence and policy in the globalized response to AIDS. Current Opinion in HIV and AIDS, 3(4), 477-480.
DOI
2007 Cooper, D., Cahn, P., Lewin, S., Kaldor, J., McClure, C., Kort, R., & Boyd, M. (2007). The Sydney Declaration: a call to scale up research. Lancet, 370(9581), 7-8.
DOI Scopus13 Europe PMC9
2007 Boyd, M. (2007). Indinavir: The forgotten HIV-protease inhibitor. Does it still have a role?. Expert Opinion on Pharmacotherapy, 8(7), 957-964.
DOI Scopus13 Europe PMC9
2007 Kerr, S., Duncombe, C., Avihingsanon, A., Ananworanich, J., Boyd, M., Sopa, B., . . . Ruxrungtham, K. (2007). Dyslipidemia in an Asian population after treatment for two years with protease inhibitor-containing regimens. Journal of the International Association of Physicians in AIDS Care, 6(1), 36-46.
DOI Scopus9 Europe PMC6
2007 Boyd, M., & Hedger, S. (2007). An unusual cause of severe metabolic acidosis [5]. Medical Journal of Australia, 186(3), 158.
2007 Boyd, M., & Cooper, D. (2007). Second-line combination antiretroviral therapy in resource-limited settings: Facing the challenges through clinical research. AIDS, 21(SUPPL. 4), S55-S63.
DOI Scopus31 Europe PMC27
2007 Srasuebkul, P., Ungsedhapand, C., Ruxrungtham, K., Boyd, M., Phanuphak, P., Cooper, D., & Law, M. (2007). Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment. HIV Medicine, 8(1), 46-54.
DOI Scopus12 Europe PMC9
2007 Boyd, M., Menon, P., Graves, S., & Gordon, D. (2007). A febrile illness with generalized papular rash involving the palms and soles. Clinical Infectious Diseases, 44(5), 704-756.
DOI
2007 Snelling, T., Ossowicz, C., & Boyd, M. (2007). Case report: Co-infections in an HIV-infected man from Malawi. American Journal of Tropical Medicine and Hygiene, 76(1), 180-181.
2007 Autar, R., Boyd, M., Wit, F., Ruxrungtham, K., Sankote, J., Lange, J., . . . Reiss, P. (2007). Relationships between drug exposure, changes in metabolic parameters and body fat in HIV-infected patients switched to a nucleoside sparing regimen. Antiviral Therapy, 12(8), 1265-1271.
Scopus5 Europe PMC5
2006 Boyd, M., Carr, A., Ruxrungtham, K., Srasuebkul, P., Bien, D., Law, M., . . . Reiss, P. (2006). Changes in body composition and mitochondrial nucleic acid content in patients switched from failed nucleoside analogue therapy to ritonavir-boosted indinavir and efavirenz. Journal of Infectious Diseases, 194(5), 642-650.
DOI Scopus23 Europe PMC18
2006 Boyd, M., Srasuebkul, P., Ruxrungtham, K., Mackenzie, P., Uchaipichat, V., Stek, M., . . . Miners, J. (2006). Relationship between hyperbilirubinaemia and UDP-glucuronosyltransferase 1A1 (UGT1A1) polymorphism in adult HIV-infected Thai patients treated with indinavir. Pharmacogenetics and Genomics, 16(5), 321-329.
DOI Scopus43 Europe PMC23
2006 Boyd, M., Siangphoe, U., Ruxrungtham, K., Reiss, P., Mahanontharit, A., Lange, J., . . . Burger, D. (2006). The use of pharmacokinetically guided indinavir dose reductions in the management of indinavir-associated renal toxicity. Journal of Antimicrobial Chemotherapy, 57(6), 1161-1167.
DOI Scopus18 Europe PMC7
2006 Boyd, M., Dixit, N., Siangphoe, U., Buss, N., Salgo, M., Lange, J., . . . Ruxrungtham, K. (2006). Viral decay dynamics in HIV-infected patients receiving ritonavir-boosted saquinavir and efavirenz with or without enfuvirtide: A randomized, controlled trial (HIV-NAT 012). Journal of Infectious Diseases, 194(9), 1319-1322.
DOI Scopus11 Europe PMC6
2006 Boyd, M., Burger, D., Phanuphak, P., & Cooper, D. (2006). Maintenance of successful ritonavir-boosted indinavir and efavirenz therapy in an HIV-infected patient with tuberculosis [4]. AIDS, 20(7), 1083-1085.
DOI Scopus2 Europe PMC2
2006 Boyd, M., Srasuebkul, P., Khongphattanayothin, M., Ruxrungtham, K., Hassink, E., Duncombe, C., . . . Phanuphak, P. (2006). Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated patients: A randomized, open-label trial with 112 weeks of follow-up (HIV-NAT 005). Antiviral Therapy, 11(2), 223-232.
Scopus14 Europe PMC10
2006 Kong, A., Koukourou, A., Boyd, M., & Crowe, G. (2006). Metastatic adenocarcinoma mimicking 'target sign' of cerebral tuberculosis. Journal of Clinical Neuroscience, 13(9), 955-958.
DOI Scopus12 Europe PMC7
2006 Boyd, M., & Rogers, W. (2006). Industry and bioethics: What price the relationship? [3]. PLoS Medicine, 3(6), 0933.
DOI Scopus1 Europe PMC1
2006 Boyd, M., & Reiss, P. (2006). The long-term consequences of antiretroviral therapy: A review. Journal of HIV Therapy, 11(2), 26-35.
Scopus14 Europe PMC12
2006 Boyd, M., Clezy, K., Lindley, R., & Pearce, R. (2006). Pandemic influenza: Clinical issues. Medical Journal of Australia, 185(10 SUPPL.), S44-S47.
Scopus19 Europe PMC11
2006 Boyd, M., & Reiss, P. (2006). Erratum: The long-term effects of antiretroviral therapy: A review (Journal of HIV Therapy 11, 2 (28)). Journal of HIV Therapy, 11(3).
2005 Boyd, M., Mootsikapun, P., Burger, D., Chuenyam, T., Ubolyam, S., Mahanontharit, A., . . . Ruxrungtham, K. (2005). Pharmacokinetics of reduced-dose indinavir/ritonavir 400/100 mg twice daily in HIV-1-infected Thai patients. Antiviral Therapy, 10(2), 301-307.
Scopus38 Europe PMC27
2005 Boyd, M., Siangphoe, U., Ruxrungtham, K., Duncombe, C., Stek, M., Lange, J., . . . Phanuphak, P. (2005). Indinavir/ritonavir 800/100 mg bid and efavirenz 600 mg qd in patients failing treatment with combination nucleoside reverse transcriptase inhibitors: 96-week outcomes of HIV-NAT 009. HIV Medicine, 6(6), 410-420.
DOI Scopus14 Europe PMC6
2004 Ananworanich, J., Cheunyam, T., Teeratakulpisarn, S., Boyd, M., Ruxrungtham, K., Lange, P., . . . Phanuphak, P. (2004). Creation of a drug fund for post-clinical trial access to antiretrovirals. Lancet, 364(9428), 101-102.
DOI Scopus16 Europe PMC9
2004 Law, W., Duncombe, C., Mahanontharit, A., Boyd, M., Ruxrungtham, K., Lange, J., . . . Dore, G. (2004). Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort. AIDS, 18(8), 1169-1177.
DOI Scopus121 Europe PMC87
2004 Ruxrungtham, K., Boyd, M., Bellibas, S., Zhang, X., Dorr, A., Kolis, S., . . . Patel, I. (2004). Lack of interaction between enfuvirtide and ritonavir or ritonavir-boosted saquinavir in HIV-1-infected patients. Journal of Clinical Pharmacology, 44(7), 793-802.
DOI Scopus23 Europe PMC14
2003 Law, W. P., Dore, G. J., Duncombe, C. J., Mahanontharit, A., Boyd, M. A., Ruxrungtham, K., . . . Cooper, D. A. (2003). Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001.. AIDS (London, England), 17(15), 2191-2199.
DOI Europe PMC60
2003 Law, W., Dore, G., Duncombe, C., Mahanontharit, A., Boyd, M., Ruxrungtham, K., . . . Cooper, D. (2003). Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001. AIDS, 17(15), 2191-2199.
DOI Scopus95
2003 Boyd, M., Zhang, X., Dorr, A., Ruxrungtham, K., Kolis, S., Nieforth, K., . . . Patel, I. (2003). Lack of Enzyme-Inducing Effect of Rifampicin on the Pharmacokinetics of Enfuvirtide. Journal of Clinical Pharmacology, 43(12), 1382-1391.
DOI Scopus39 Europe PMC26
2003 Boyd, M., Aarnoutse, R., Ruxrungtham, K., Stek, M., Van Heeswijk, R., Lange, J., . . . Burger, D. (2003). Pharmacokinetics of indinavir/ritonavir (800/100 mg) in combination with efavirenz (600 mg) in HIV-1-infected subjects. Journal of Acquired Immune Deficiency Syndromes, 34(2), 134-139.
DOI Scopus18 Europe PMC14
2003 Burger, D., Boyd, M., Duncombe, C., Felderhof, M., Mahanontharit, A., Ruxrungtham, K., . . . Reiss, P. (2003). Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients. Journal of Antimicrobial Chemotherapy, 51(5), 1231-1238.
DOI Scopus56 Europe PMC34

Book Chapters

Conference Items

Year Citation
2016 Boyd, M. A. (2016). HIV in Myanmar.. Poster session presented at the meeting of 2016 International Congress for Tropical Medicine and Malaria. Brisbane, Queensland, Australia.
2014 Holt, S., Gracey, D., Mudge, D., Irish, A., Sevastos, J., Walker, R., . . . Boyd, M. (2014). RENAL FUNCTION TESTING IN PATIENTS ON TENOFOVIR ANTIVIRAL THERAPY. Poster session presented at the meeting of NEPHROLOGY. WILEY-BLACKWELL.
Grants and Funding
Category 1
2014 - 2017 Clinical Development Award clinical support for 4 years NHMRC 2014: $404,884 AUD
2013 Project Grant award support of the SECOND-LINE study NHMRC $449,584.40 AUD

 

Category 2
2014 Australian Award Fellowship support of the combined UNSW/U Sydney Global Intensive Professional Program in HIV (GIPPH) Australian Commonwealth Government Department of Foreign Affairs & Trade. $656,888.
2013 Australian Award Fellowships support of the combined UNSW/U Sydney Global Intensive Professional Program in HIV (GIPPH) AusAID $698,160.00

 

Category 3
2015 In support of the development of capacity to measure ARV levels in human tissues: Merck & Co. IISP grant $20,000 UAD
2015 Award in support of Faster and smarter identification of at-risk sexually transmitted infection patients via online, mobile and social platforms auDA foundation $20,000 AUD
2014 Award in project support of The association between virological failure and lopinavir plasma drug levels in the SECOND-LINE trial Gilead Australia Fellowship Research Grants 2015: $30,000 AUD
2014 Independent initiative grant support for an analysis of bone turnover, immune activation and inflammatory biomarkers in the SECOND-LINE DXA-substudy, Grants Merck Global Affairs 2014: $304,064 AUD
2012 Award for support of the RATE study Gilead Australia Fellowship Research Grants 2013: $20,000 AUD
2012 Support of the SECOND-LINE study The Foundation for AIDS Research 2012: $125,000 USD
2012 Support of the SECOND-LINE study Merck & Co. $1,000,000 USD.
2011 Support of the SECOND-LINE study The Foundation for AIDS Research 2011: $125,000 USD
2010 Support of the SECOND-LINE study The Foundation for AIDS Research 2010: $125,000 USD
2009 Support of the SECOND-LINE study Abbott Inc. $600,000 AUD
2009 Support of the SECOND-LINE study Merck & Co. 2009: $1,100,000 USD
2008 Support of the Encore program Bill and Melinda Gates Foundation $12,416,901 USD

Board Memberships

Date Role Board name Institution name Country
2015 - ongoing Member , Scientific and Program Committee of the Asia Pacific AIDS & Co-infections Asia Pacific AIDS & Co-infections (APAAC) Conference 2016 Asia Pacific AIDS & Co-infections Asia Pacific AIDS & Co-infections (APAAC)

Committee Memberships

Date Role Committee Institution Country
2015 - ongoing Chair ASHM International Advisory Group
2014 - ongoing Member Australian National HIV Pre-Exposure Prophylaxis (PrEP) Guidance Committee
2014 - ongoing Chair RACP Working Group
2014 - ongoing President Australasian Society for HIV Medicine (ASHM)
2014 - ongoing Chair Gilead ‘HIV and the Body’ educational meeting faculty
2013 - ongoing Chair Lyell McEwin Hospital, Discipline of Medicine, School of Medicine University of Adelaide
2013 - ongoing Member NEAT-id (European Treatment Network for HIV, Hepatitis and Global Infectious Diseases)
2013 - ongoing Member Australasian Society for HIV Medicine (ASHM) Clinical Guidance Committee
2013 - ongoing Chair National Program Theme B Committee for the ASHM 2013 National Conference
2012 - ongoing Member Kirby Institute Higher Degree Committee and Annual Post-Graduate Progress Review academic staff
2012 - ongoing Member ASID Prosthetic Joint Infection Trial Steering Committee
2012 - ongoing Member ASHM NSW HIV Shared Care Workshop Committee
2012 - ongoing Member Australian Society for Infectious Disease (ASID) Native Joint Infection Trial Steering Committee
2011 - 2014 Vice-President Australasian Society for HIV Medicine (ASHM)
2010 - ongoing Member Australian HIV Observational Database (AHOD) Steering Committee
2009 - ongoing Vice-President Australasian Society for HIV Medicine
2009 - ongoing Member ASHM Risk Management and Audit Sub-Committee
2005 - 2009 Board Member Australasian Society for HIV Medicine
2005 - ongoing Board Member Australasian Society for HIV Medicine (ASHM)
1999 - 2005 Member Australasian Society for HIV Medicine

Consulting/Advisories

Date Institution Department Organisation Type Country
2014 - ongoing International Advisory Board, Lancet HIV
2014 - ongoing Merck Australian HIV Advisory Board
2013 - ongoing ASHM NSW Expert Advisory Committee
2013 - ongoing Gilead Sciences International HIV Advisory Board

Editorial Boards

Date Role Editorial Board Name Institution Country
2015 - ongoing Editor-In-chief AIDS Research & Therapy BMC open access journal

Industry Partnerships

Date Engagement Type Partner Name
2014 - 2016 Consultant Honorary Consultant in HIV Medicine, The Albion Centre
2013 - ongoing Consultant HIV and Infectious Diseases Specialist Consultant, Holdsworth House Medical Practice
Position
Chailr of Medicine
Phone
0881829653
Building
Lyell McEwin Hospital
Org Unit
Medicine

top